Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
ALS Phase II Study of NX210cNutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorderActive, not recruitingPhase 22025-12-24NCT06365216

2 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
ACT4ALS network1
Axoltis Pharma1

16 results · Page 1 of 1

Swipe the table sideways for more columns.